The toxic effects of desferrioxamine (Q38648395)

5 September 2017

1 reference

title

The toxic effects of desferrioxamine (English)

1 reference

5 September 2017

1

1 reference

5 September 2017

Huehns ER

2

1 reference

5 September 2017

language of work or name

1 reference

1 April 1989

1 reference

Best Practice and Research: Clinical Haematology

5 September 2017

published in

1 reference

5 September 2017

volume

2

1 reference

5 September 2017

issue

2

1 reference

5 September 2017

page(s)

459-474

1 reference

Successful removal of aluminium from patient with dialysis encephalopathy

5 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine administered intravenously by infusion causes a reduction in the electroretinogram in rabbits anaesthetized with urethane.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular changes in patients undergoing long-term desferrioxamine treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Acute Renal Insufficiency Occurring during Intravenous Desferrioxamine Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Mucormycosis infection in dialysis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Prooxidant action of desferrioxamine: Fenton-like production of hydroxyl radicals by reduced ferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Visual loss in patient on high-dose subcutaneous desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactoid reaction.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Enteritis, abscess, and septicemia due to Yersinia enterocolitica in a child with thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine B: reversible side effects of high daily doses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine-Induced Acute Neurosensorial Deafness

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular effects of systemic siderosis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine (Desferal) and superoxide free radicals. Formation of an enzyme-damaging nitroxide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular toxicity of high-dose intravenous desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine in ocular siderosis: a long-term electrophysiological evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Auditory Involvement in Thalassemia Major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Experimental study of the retinal toxicity of hemoglobinic iron

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Editorial: Polyarthritis and Yersinia enterocolitica infection

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Role of Iron in Microbe-Host Interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Neurotoxicity associated with deferoxamine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Electroretinographic and visual-evoked potential abnormalities in patients with beta-thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Yersinia pseudotuberculosis septicaemia in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

The role of superoxide and hydroxyl radicals in phospholipid peroxidation catalysed by iron salts

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ferrous ion-EDTA-stimulated phospholipid peroxidation. A reaction changing from alkoxyl-radical- to hydroxyl-radical-dependent initiation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

E.N.T. complications in thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Antibiotics in Yersinia enterocolitica infections

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

The Effect of Desferoxamine on Fibroblasts and Collagen Formation in Cell Cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Yersinia enterocolitis in iron overload.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Pneumocystis carinii pneumonia as a complication of desferrioxamine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Thalassemia major (homozygous beta-thalassemia): A survey of 138 cases with emphasis on neurologic and muscular aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

THE RETINA IN HAEMOCHROMATOSIS.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Tinnitus in a patient with beta-thalassaemia intermedia on long-term treatment with desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Septicaemia due to Yersinia enterocolitica after oral overdoses of iron

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Rapid desensitisation for desferrioxamine anaphylactic reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Total management of thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Long-term desferrioxamine therapy in thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

COPPER CHELATION AND THE NEURO-OPHTHALMIC TOXICITY OF DESFERRIOXAMINE

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular toxicity after a single intravenous dose of desferrioxamine in 2 hemodialyzed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Accumulation of iron by yersiniae

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Iron chelation using subcutaneous infusions of diethylene triamine penta-acetic acid (DTPA).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Treatment of early stages of dialysis encephalopathy by aluminium depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Treatment of rheumatoid arthritis with desferrioxamine: relation between stores of iron before treatment and side effects

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Reassessment of the Use of Desferrioxamine B in Iron Overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Continuous subcutaenous administration of deferoxamine in patients with iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Iron overdose during pregnancy: successful therapy with deferoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

DESFERRIOXAMINE AND SYSTEMIC YERSINIOSIS

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Ocular toxicity of desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Leukocyte Alkaline Phosphatase (LAP) A Useful Marker of Zinc Status in β-Thalassemic Patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Desferrioxamine, ocular toxicity, and trace metals

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Successful pregnancy in transfusion-dependent thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Thrombocytopenia associated with intravenous desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

Reversal of desferrioxamine induced auditory neurotoxicity during treatment with Ca-DTPA

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3536%2889%2980027-7

7 January 2021

10.1016/S0950-3536(89)80027-7

Identifiers

DOI

1 reference

5 September 2017

1 reference